A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ontamalimab (Primary)
- Indications Crohn's disease; Inflammation; Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms AIDA
- Sponsors Shire; Shire Human Genetic Therapies; Takeda
- 18 Dec 2018 Planned End Date changed from 11 Feb 2025 to 3 Jun 2025.
- 19 Jul 2018 Planned End Date changed from 3 Jun 2025 to 11 Feb 2025.
- 19 Jul 2018 Planned primary completion date changed from 3 Jun 2025 to 11 Feb 2025.